Glycomet
intended to target high blood sugar levels and to support metabolic control in diabetes.
Strengths: 500mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Glucophage
- Therapeutic class
Biguanide Antidiabetic
- Pharmacological class
Biguanide
- Known off-label uses
polycystic ovary syndrome
- Contraindications
renal impairment; diabetic ketoacidosis; severe hepatic impairment
- Minor side effects
nausea; diarrhoea; abdominal pain; loss of appetite
- Moderate side effects
metallic taste; vitamin B12 deficiency
- Serious side effects
lactic acidosis — requires immediate medical attention
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
USV Private Limited
- Onset Time
1–2 weeks
- Duration
indefinite
- Storage instructions
Store at room temperature in a dry place.
- Drug interactions
alcohol; iodinated contrast agents; corticosteroids
- Age restrictions
Suitable for adults; specific paediatric approval varies by formulation.
Precautions and warnings
discontinue before surgery; regular blood glucose monitoring necessary; risk of vitamin B12 deficiency
Patient summary
intended to target high blood sugar levels and to support metabolic control in diabetes.
Mechanism of action
Reduces hepatic glucose production and improves insulin sensitivity, enhancing peripheral glucose uptake without causing hypoglycaemia.
Pregnancy and breastfeeding
Pregnancy: Insulin is preferred for glucose control during pregnancy. Breastfeeding: Generally considered safe.
Glycomet
intended to target high blood sugar levels and to support metabolic control in diabetes.
Editorial Notes
- Active ingredient(s): Metformin
- Listed indication(s): Type 2 Diabetes Mellitus